Compare · LLY vs ORGS
LLY vs ORGS
Side-by-side comparison of Eli Lilly and Company (LLY) and Orgenesis Inc. (ORGS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and ORGS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.02T, about 15534.2x ORGS ($65.4M).
- Over the past year, LLY is up 41.3% and ORGS is up 0.0% - LLY leads by 41.3 points.
- LLY has hit the wire 21 times in the past 4 weeks while ORGS has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 0 for ORGS).
- Company
- Eli Lilly and Company
- Orgenesis Inc.
- Price
- $1082.46+1.70%
- $2.13-33.80%
- Market cap
- $1.02T
- $65.4M
- 1M return
- +11.80%
- +0.00%
- 1Y return
- +41.27%
- +0.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 21
- 0
- Recent ratings
- 25
- 0
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Orgenesis Inc.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. sThe company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. The company was incorporated in 2008 and is based in Germantown, Maryland.
Latest LLY
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
- Foundayo and Zepbound now covered for millions of Americans
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Lilly announces three acquisitions to build infectious disease portfolio
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
- SEC Form 8-K filed by Eli Lilly and Company
- Director Sulzberger Gabrielle was granted 5 shares, increasing direct ownership by 0.17% to 2,987 units (SEC Form 4)
Latest ORGS
- SEC Form PRE 14A filed by Orgenesis Inc.
- SEC Form 10-K filed by Orgenesis Inc.
- Orgenesis Inc. filed SEC Form 8-K: Leadership Update
- Orgenesis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Orgenesis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Orgenesis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Orgenesis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Orgenesis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Orgenesis Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- SEC Form NT 10-Q filed by Orgenesis Inc.